If the conditions for drug approval and marketing become more severe, pharmaceutical companies will be forced to produce fewer me-too drugs and more products of clinical importance. Requiring longer testing periods, and possibly extra resources, could be compensated by new drugs’ greater longevity on the market, and patent coverage could be extended.
如果药物审批和营销的环境变得更为严厉，各制药公司将会被迫减产那些亦步亦趋的药品而增产有临床重要性的药品。更长的试验期和额外的资源成本可以通过新药在市场上更长的生命周期来补偿，专利覆盖面也可以扩大。